Open History Table in phpPgAdmin
| Type of Change | indholder | ind_number | protocol_size | parent_protocol | protocol_population | current_version | network_name | protocol_duration_in_months | operations_directory | protocol_name | version | exclude_report | daidswsmaintain_exclude | daidsstudy_id | stage_name | indanniversary_date | record_add_user | protocol_title | protocol_rationale | partner_protocol | ind_contact | record_mod_dt | root_protocol_id | protocol_description | ind_report_due_date | status_name | protocol_id | record_mod_user | trial_design_name | record_add_dt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSERTED | DAIDS | 55.690 | None | None | None | 1 | MTN | 24.0 | None | MTN 018 - Tenofovir Expanded Access | 1 | 0 | 0 | 11818 | Protocol Development | None | FHCRC\missy | Committed to Having Options for Interventions to Control the Epidemic: a Follow-up Study to MTN-003 | None | None | None | 2011-02-03 09:20:33.943000 | 1056 | Phase IIIB Tenofovir gel expanded access | None | In Development | 1056 | FHCRC\missy | Phase IIIB | 2011-02-03 09:16:50.350000 |
| UPDATED - Before | International Partnership for Microbicides (IPM) | 69,022 | 48 | None | None | 1 | MTN | 4.0 | None | MTN 012 | 1 | 0 | 0 | 11771 | Study Setup (Pending) | None | FHCRC\missy | Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures | None | None | None | 2010-11-30 11:30:50.470000 | 1022 | Dapivirine Male Tolerance | None | In Development | 1022 | FHCRC\missy | Phase I | 2010-01-15 14:02:40.477000 |
| UPDATED - After | International Partnership for Microbicides (IPM) | 69,022 | 48 | None | None | 1 | MTN | 4.0 | None | MTN 012 | 1 | 0 | 0 | 11771 | Study Setup (Pending) | None | FHCRC\missy | Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures | None | None | None | 2011-02-03 07:27:47.250000 | 1022 | Dapivirine Male Tolerance | None | In Development | 1022 | FHCRC\missy | Phase I | 2010-01-15 14:02:40.477000 |
| UPDATED - Before | DAIDS | None | 32 | None | None | 1 | MTN | 6.0 | None | MTN 013 | 1 | 0 | 0 | 11772 | Protocol Development | None | FHCRC\missy | Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring | None | None | None | 2011-01-07 12:43:15.373000 | 1023 | IPM Dap/Mav Ring Study | None | In Development | 1023 | FHCRC\missy | Phase I | 2010-01-15 14:05:16.867000 |
| UPDATED - After | DAIDS | None | 32 | None | None | 1 | MTN | 6.0 | None | MTN 013 | 1 | 0 | 0 | 11772 | Protocol Development | None | FHCRC\missy | Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring | None | None | None | 2011-02-03 07:31:43.093000 | 1023 | IPM Dap/Mav Ring Study | None | In Development | 1023 | FHCRC\missy | Phase I | 2010-01-15 14:05:16.867000 |
| UPDATED - Before | CONRAD | None | 90 | None | healthy HIV-uninfected females 15-18 years old | 1 | MTN | 12.0 | None | Tenofovir in adolescents | 1 | 0 | 0 | None | Concept (Proposed) | None | FHCRC\missy | Safety and Tolerability of 1% Tenofovir Gel in Adolescent Females | None | None | None | 2011-01-07 11:12:34.873000 | 1048 | Tenofovir in adolescents | None | In development | 1048 | FHCRC\missy | Phase II | 2010-12-16 16:24:56.560000 |
| UPDATED - After | CONRAD | None | 90 | None | healthy HIV-uninfected females 15-18 years old | 1 | MTN | 12.0 | None | MTN-021 - Tenofovir in adolescents | 1 | 0 | 0 | None | Concept (Proposed) | None | FHCRC\missy | Safety and Tolerability of 1% Tenofovir Gel in Adolescent Females | None | None | None | 2011-02-03 08:49:56.497000 | 1048 | MTN-021 | None | In development | 1048 | FHCRC\missy | Phase II | 2010-12-16 16:24:56.560000 |
| UPDATED - Before | DAIDS | None | None | None | 180 HIV-uninfected pregnant women 18-45 years old | 1 | MTN | 12.0 | None | Tenofovir in Pregnancy | 1 | 0 | 0 | None | Concept (Proposed) | None | FHCRC\missy | Extended Safety of Tenofovir Gel in Pregnancy | None | None | None | 2011-01-07 11:21:21.913000 | 1050 | Tenofovir in Pregnancy | None | In development | 1050 | FHCRC\missy | Phase II | 2011-01-07 11:15:11.637000 |
| UPDATED - After | DAIDS | None | None | None | 180 HIV-uninfected pregnant women 18-45 years old | 1 | MTN | 12.0 | None | MTN-019 - Tenofovir in Pregnancy | 1 | 0 | 0 | None | Concept (Proposed) | None | FHCRC\missy | Extended Safety of Tenofovir Gel in Pregnancy | None | None | None | 2011-02-03 08:50:24.713000 | 1050 | MTN-019 | None | In development | 1050 | FHCRC\missy | Phase II | 2011-01-07 11:15:11.637000 |
| UPDATED - Before | None | None | None | None | 32 HIV-uninfected, sexually-active, heterosexual couples | 1 | MTN | 9.0 | None | MTN-011 | 1 | 0 | 0 | None | Protocol Development | None | FHCRC\missy | Evaluation of the Pharmacokinetics and Pharmacodynamics of Tenofovir Gel Following Coitus | None | None | None | 2011-02-02 17:57:45.503000 | 1053 | MTN-011 | None | In Development | 1053 | FHCRC\missy | Phase I | 2011-02-02 17:55:23.520000 |
| UPDATED - After | None | None | None | None | 32 HIV-uninfected, sexually-active, heterosexual couples | 1 | MTN | 9.0 | None | MTN-011 - PK/PD of TNF Following Coitus | 1 | 0 | 0 | None | Protocol Development | None | FHCRC\missy | Evaluation of the Pharmacokinetics and Pharmacodynamics of Tenofovir Gel Following Coitus | None | None | None | 2011-02-03 09:22:49.363000 | 1053 | MTN-011 | None | In Development | 1053 | FHCRC\missy | Phase I | 2011-02-02 17:55:23.520000 |
| UPDATED - Before | None | None | None | None | HIV-uninfected African women | 1 | MTN | 24.0 | None | MTN-020 | 1 | 0 | 0 | None | Protocol Development | None | FHCRC\missy | IPM Phase III Intravaginal Ring Study - Dapivirine | None | None | None | 2011-02-02 18:02:52.957000 | 1054 | MTN-020 | None | In Development | 1054 | FHCRC\missy | Phase III | 2011-02-02 18:02:03.800000 |
| UPDATED - After | None | None | None | None | HIV-uninfected African women | 1 | MTN | 24.0 | None | MTN-020 - IPM Phase III Ring | 1 | 0 | 0 | None | Protocol Development | None | FHCRC\missy | IPM Phase III Intravaginal Ring Study - Dapivirine | None | None | None | 2011-02-03 08:50:47.463000 | 1054 | MTN-020 | None | In Development | 1054 | FHCRC\missy | Phase III | 2011-02-02 18:02:03.800000 |
| UPDATED - Before | None | None | None | None | 32 HIV-uninfected women | 1 | MTN | 6.0 | None | MTN-014 | 1 | 0 | 0 | None | Concept (Proposed) | None | FHCRC\missy | A PHASE 1 CROSSOVER TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF 1% TENOFOVIR GEL IN THE RECTAL AND VAGINAL COMPARTMENTS FOLLOWING LOCAL ADMINISTRATION IN EACH ONE OF THESE COMPARTMENTS | None | None | None | 2011-02-02 18:14:10.800000 | 1055 | MTN-014 | None | In development | 1055 | FHCRC\missy | Phase I | 2011-02-02 18:14:10.800000 |
| UPDATED - After | None | None | None | None | 32 HIV-uninfected women | 1 | MTN | 6.0 | None | MTN-014 - Safety and PK of TNF Vag/Rectal | 1 | 0 | 0 | None | Concept (Proposed) | None | FHCRC\missy | A PHASE 1 CROSSOVER TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF 1% TENOFOVIR GEL IN THE RECTAL AND VAGINAL COMPARTMENTS FOLLOWING LOCAL ADMINISTRATION IN EACH ONE OF THESE COMPARTMENTS | None | None | None | 2011-02-03 09:23:53.490000 | 1055 | MTN-014 | None | In development | 1055 | FHCRC\missy | Phase I | 2011-02-02 18:14:10.800000 |
| DELETED | None | None | None | None | None | 1 | MTN | 24.0 | None | MTN 018 | 1 | 0 | 0 | None | Protocol Development | None | FHCRC\missy | None | None | None | None | 2011-02-02 18:15:07.720000 | 1024 | Phase IIIB Tenofovir gel expanded access | None | In Development | 1024 | FHCRC\missy | Phase IIIB | 2010-01-15 14:08:34.617000 |